Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4.

Front Oncol · 2013 · PMC3711044 · PMID 23875174

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Further analysis showed that patients with increases in 5T4 antibodies at week 7 (after the third vaccination) above the median fold showed a trend toward increased PFS and a significant improvement in OS ( p = 0.01) compared to patients with antibody levels below the median.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.